Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Epothilone D (KOS-862)
Epothilone D · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Epothilone D (KOS-862) | DRUG | - |
Inclusion Criteria: 1. Diagnosis of histologically documented, advanced stage, primary or metastatic adult solid tumors that are refractory to standard therapy or for which no curative standard therapy exists. This includes but is not limited to cancers of the breast, ovary, head and neck, esophagu...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCA036978 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE1 | Revumenib |
Epothilone D is an investigational small molecule being studied for the treatment of neoplasms, specifically advanced solid tumors. It is in Phase 1 clinical development in oncology and is not approved for any indication. The single completed trial enrolled 45 adult patients with advanced solid tumors in the United States.
Epothilone D targets tubulin proteins, including TUBB4B, TUBB1, TUBA3C, TUBA4A, TUBB3, and TUBA1A. It belongs to the tubulin stabiliser class, meaning it acts on these microtubule components. This mechanism is being explored in oncology as a way to interfere with tumor cell division.
Epothilone D is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is responsible for its clinical development in oncology.
Epothilone D is in Phase 1 clinical development. It is investigational and has not been approved by the FDA for any indication. The only recorded trial is a completed Phase 1 study, and there are currently no active trials.
Epothilone D has been studied in one completed Phase 1 trial, NCT00030173, titled A Trial to Evaluate Epothilone D in Patients With Advanced Solid Tumors. The trial enrolled 45 adults with neoplasms in the United States. It was uncontrolled, non-randomized, and not blinded.
Yes, Epothilone D is also known as KOS-862. Both names refer to the same investigational small molecule developed by Bristol-Myers Squibb for advanced solid tumors. It is currently in Phase 1 development.